Lutetium oxodotreotide (<sup>177</sup>Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.

Smith-Palmer, J; Leeuwenkamp, O R; Virk, J; Reed, N

Lutetium oxodotreotide (¹⁷⁷Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.

Smith-Palmer, J; Leeuwenkamp, O R; Virk, J; Reed, N.

Affiliation

Smith-Palmer J; Ossian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland. smith-palmer@ossianconsulting.com.
Leeuwenkamp OR; Advanced Accelerator Applications/A Novartis company, Geneva, Switzerland.
Virk J; Advanced Accelerator Applications/A Novartis company, London, UK.
Reed N; Beatson Oncology Centre, Gartnavel General Hospital, Glasgow, UK.

BMC Cancer ; 21(1): 10, 2021 Jan 05.

Article de En | MEDLINE | ID: mdl-33402120

Sujet(s)
Mots clés

Cost; Cost-effectiveness; Gastroenteropancreatic neuroendocrine tumors; Radionuclides; Scotland

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Composés organométalliques / Tumeurs du pancréas / Tumeurs de l'estomac / Octréotide / Analyse coût-bénéfice / Tumeurs neuroendocrines / Radiopharmaceutiques / Tumeurs de l'intestin / Lutétium Type d'étude: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limites: Humans Langue: En Journal: BMC Cancer Sujet du journal: NEOPLASIAS Année: 2021 Type de document: Article Pays d'affiliation: Suisse

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google